Artificial liver support systems.
Acute-On-Chronic Liver Failure
/ blood
Bilirubin
/ blood
Creatinine
/ blood
Dialysis
/ instrumentation
Female
Hemodiafiltration
/ instrumentation
Humans
Liver Failure, Acute
/ blood
Liver, Artificial
Male
Sorption Detoxification
/ instrumentation
Treatment Outcome
Urea
/ blood
gamma-Glutamyltransferase
/ blood
artificial
extracorporeal circulation
liver
transplant
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
31
08
2020
received:
23
06
2020
accepted:
03
09
2020
pubmed:
13
9
2020
medline:
2
10
2021
entrez:
12
9
2020
Statut:
ppublish
Résumé
Artificial liver systems are used to bridge between transplantation or to allow a patient's liver to recover. They are used in patients with acute liver failure (ALF) and acute-on-chronic liver failure. There are five artificial systems currently in use: molecular adsorbent recirculating system (MARS), single-pass albumin dialysis (SPAD), Prometheus, selective plasma filtration therapy, and hemodiafiltration. The aim is to compare existing data on the efficiency of these devices. A literature search was conducted using online libraries. Inclusion criteria included randomized control trials or comparative human studies published after the year 2000. A systematic review was conducted for the five individual devices with a more detailed comparison of the biochemistry for the SPAD and MARS systems. Eighty-nine patients were involved in the review comparing SPAD and MARS. Results showed that there was an average reduction in bilirubin (-53 μmol/L in MARS and -50 μmol/L in SPAD), creatinine (-19.5 μmol/L in MARS and -7.5 μmol/L in SPAD), urea (-0.9 mmol/L in MARS and -0.75 mmol/L in SPAD), and gamma-glutamyl transferase (-0.215 μmol/L·s in MARS and -0.295 μmol/L·s in SPAD) in both SPAD and MARS. However, there was no significant difference between the changes in the two systems. This review demonstrated that both MARS and SPAD aid recovery of ALF. There is no difference between the efficiency of MARS and SPAD. Because of the limited data, there is a need for more randomized control trials. Evaluating cost and patient preference would aid in differentiating the systems.
Substances chimiques
Urea
8W8T17847W
Creatinine
AYI8EX34EU
gamma-Glutamyltransferase
EC 2.3.2.2
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1179Informations de copyright
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Trefts E, Gannon M, Wasserman DH. The Liver. Curr. Biol. 2017; 27: r1147-r1151.
Figaro S, Pereira U, Dumé A-S et al. SUPPLIVER: bioartifical supply for liver failure. IRBM 2015; 36: 101-109 *An excellent study of the liver and how bioartificial liver devices are developed and tested.
Bernal W, Wendon J. Acute liver failure. New England Journal of Medicine. 2013; 369: 2525-2534.
Abbas Z, Shazi L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatology International. 2015; 9: 366-372.
Chan AC, Fan ST, Lo CM et al. Liver transplantation from acute on chronic liver failure. Hepatol Int. 2009; 3: 571-581.
Prince MI, Hudson M. Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages. Postgrad. Med. J. 2002; 78: 135-141.
Schonfeld W, The Lewin Group, San Francisco et al. The cost effectiveness of an extra-corporeal liver assist device as a bridge to transplant for patients with fulminant hepatic failure. Hepatology 2001; 34: A190.
Krisper P, Stadlbauer V, Stauber RE. Clearing of toxic substance: are there differences between the available liver support devices? Liver International 2011; 31: 5-8.
Yonekawa C, Nakae H, Tajimi K, Asanuma Y. Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure. Artif. Organs 2005; 29: 324-328.
Nakae H, Yonekawa C, Moon S, Tajimi K. The series-parallel circuit in the treatment of fulminant hepatitis. Ther. Apher. Dial. 2004; 8: 153-159.
Zheng Z, Li X, Li Z, Ma X. Artificial and bioartifical liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Experimental and Therapeutic Medicines 2013; 6: 929-936 **A large meta analysis comparing artificial and bioartificial liver device systems.
PRISMA. [Internet]. Oxford. 2015. [cited 2019 Jan 31]. Available from: http://www.prisma-statement.org
Consort. [Internet]. 2019 [cited 2019 Jan 31]. Available from: http://www.consort-statement.org/checklists/view/32--consort-2010/66-title
BMJ. [Internet]. 2019 [cited 2019 Jan 31]. Available from: https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/
García Martínez J, Bendjelid K. Artificial liver support systems: what is new over the last decade? Annals of Intensive Care 2018; 8: 109.
George J. Artificial liver support systems. J. Assoc. Physicians India 2004; 52: 719-722.
Stange J, Mitzner SR, Risler T et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartifical liver support. Artif. Organs 1999; 23: 319-330.
Marangoni R, Bellati G, Castelli A, Romagnoli E. Development of high-efficiency molecular adsorbent recirculating system: preliminary report. Artif. Organs 2014; 38: 879-883.
Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am. J. Gastroenterol. 2005; 100: 468-475.
Quintero Bernabeu J, Ortega López J, Juampérez Goñi J et al. The role of molecular adsorbent recirculating system in pediatric acute liver failure. Liver Transpl. 2018; 24: 308-310.
Gerth H, Pohlen M, Thölking G et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure-a retrospective analysis*. Crit. Care Med. 2017; 45: 1616-1624.
Gerth H, Pohlen M, Thölking G et al. Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: results from a case-control study. PLOS ONE. 2017; 12: e0175529.
Olin P, Hausken J, Foss A, Karlsen T, Melum E, Haugaa H. Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation. Scand. J. Gastroenterol. 2015; 50: 1127-1134.
Lexmond W, Van Dael C, Scheenstra R et al. Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl. 2015; 21: 369-380.
Bourgoin P, Merouani A, Phan V et al. Molecular absorbent recirculating system therapy (MARS®) in pediatric acute liver failure: a single center experience. Pediatr. Nephrol. 2013; 29: 901-908.
Donati G, La Manna G, Cianciolo G et al. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up. Artif. Organs 2013; 38: 125-134.
Cisneros-Garza L, Muñoz-Ramírez M, Muñoz-Espinoza L et al. The molecular adsorbent recirculating system as a liver support system. Summary of Mexican experience. Ann. Hepatol. 2014; 13: 240-247.
Kortgen A, Rauchfuss F, Götz M, Settmacher U, Bauer M, Sponholz C. Albumin dialysis in liver failure: comparison of molecular adsorbent recirculating system and single pass albumin dialysis: a retrospective analysis. Ther Apher Dial 2009; 13: 419-425 ** A retrospective analysis comparing the SPAD and MARS systems.
Ringe H, Varnholt V, Zimmering M et al. Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure*. Pediatr. Crit. Care Med. 2011; 12: 257-264.
Benyoub K, Muller M, Bonnet A et al. Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure. Ther. Apher. Dial. 2011; 15: 504-506.
Piechota M, Piechota A, Misztal M, Bernas S, Pietraszek-Grzywaczewska I. An evaluation of the usefulness of extracorporeal liver support techniques in patients with severe liver dysfunction. Arch. Med. Sci. 2019; 15: 99-112.
Boonsrirat U, Tiranathanagul K, Srisawat N et al. Effective bilirubin reduction by single-pass albumin dialysis in liver failure. Artif. Organs 2009; 33: 648-653.
Karvellas C, Bagshaw S, McDermid R, Stollery D, Bain V, Gibney R. A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif. 2009; 28: 151-158.
McKenzie T, Lillegard J, Nyberg S. Artificial and bioartificial liver support. Semin. Liver Dis. 2008; 28: 210-217.
Komardina E, Yaroustovsky M, Abramyan M, Plyushch M. Prometheus therapy for the treatment of acute liver failure in patients after cardiac surgery. Polish Journal of Cardio-Thoracic Surgery. 2017; 4: 230-235.
Kribben A, Gerken G, Haag S et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-789.e3.
Rifai K, Ernst T, Kretschmer U et al. Prometheus®-a new extracorporeal system for the treatment of liver failure. J. Hepatol. 2003; 39: 984-990.
Grodzicki M, Kotulski M, Leonowicz D, Zieniewicz K, Krawczyk M. Results of treatment of acute liver failure patients with use of the Prometheus FPSA system. Transplant. Proc. 2009; 41: 3079-3081.
Oppert M, Rademacher S, Petrasch K, Jörres A. Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit. Ther. Apher. Dial. 2009; 13: 426-430.
Rifai K, Hafer C, Rosenau J et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus®). Scand. J. Gastroenterol. 2006; 41: 1212-1217.
Santoro A, Faenza S, Mancini E et al. Prometheus system: a technological support in liver failure. Transplant. Proc. 2006; 38: 1078-1082.
Skwarek A, Grodzicki M, Nyckowski P et al. The use Prometheus FPSA system in the treatment of acute liver failure: preliminary results. Transplant. Proc. 2006; 38: 209-211.
Evenepoel P, Laleman W, Wilmer A et al. Detoxifying capacity and kinetics of Prometheus®-a new extracorporeal system for the treatment of liver failure. Blood Purif. 2005; 23: 349-358.
Rifai K, Ernst T, Kretschmer U et al. The Prometheus® device for extracorporeal support of combined liver and renal failure. Blood Purif. 2005; 23: 298-302.
Medgadget. (2019). Sepet™: blood purification filter for liver failure. [online] Available at: https://www.medgadget.com/2005/04/sepet_blood_pur.html [Accessed 10 Aug. 2019].
Rozga J, Malkowski P. Artificial liver support: quo vadis? Ann. Transplant. 2010; 15: 92-101.
Nakae H, Igarashi T, Tajimi K et al. A case report of hepatorenal syndrome treated with plasma diafiltration (selective plasma filtration with dialysis). Ther. Apher. Dial. 2007; 11: 391-395.
Rozga J, Umehara Y, Trofimenko A, Sadahiro T, Demetriou A. A novel plasma filtration therapy for hepatic failure: preclinical studies. Ther. Apher. Dial. 2006; 10: 138-144.
Nakao M, Nakayama N, Uchida Y et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J. Gastroenterol. 2017; 53: 752-769.
Inoue K, Watanabe T, Maruoka N et al. Japanese style intensive medical care improves prognosis for acute liver failure and the perioperative management of liver transplantation. Transplant. Proc. 2010; 42: 4109-4112.
Arata S, Nozaki A, Takizawa K et al. Hepatic failure in pregnancy successfully treated by online hemodiafiltration: chronic hepatitis B virus infection without viral genome mutation. Hepatol. Res. 2013 Dec; 43: 1356-1360. https://doi.org/10.1111/hepr.12090
Yokoi T, Oda S, Shiga H et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus. Apher. Sci. 2009; 40: 61-70.
Fujiwara K, Abe R, Yasui S, Yokosuka O, Kato N, Oda S. High recovery rate of consciousness by high-volume filtrate hemodiafiltration for fulminant hepatitis. Hepatol. Res. 2019 Feb; 49: 224-231. https://doi.org/10.1111/hepr.13255
Nand N, Verma P, Jain D. Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and/or hepatorenal syndrome. J. Assoc. Physicians India 2019; 67: 39-42.
Li M, Li J, Shi Z et al. Efficacy of various combined blood purification techniques for treating patients with non-viral acute liver failure. Cell Biochem. Biophys. 2013; 68: 571-575.
Abe T, Kobata H, Hanba Y et al. Study of plasma exchange for liver failure: beneficial and harmful effects. Ther. Apher. Dial. 2004; 8: 180-184.
Sponholz C, Matthes K, Rupp D et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure-a prospective, randomised crossover study. Critical Care 2016; 20: 2.
Collins K, Roberts E, Adeli K, Bohn D, Harvey E. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatric Nephrology 2008; 23: 1013-1016.
Zhai R, Sheu CC, Su L et al. Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis. Thorax 2009; 64: 784-790.